Eisai

Biogen Inc (NASDAQ: BIIB) shares, which ended Tuesday's session at a three-year high following a beat-and-raise second-quarter report, are experiencing continued momentum after a poster presentation on the company's Alzheimer's disease candidate co-developed with Japan's...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  What Happened Biogen and its Japanese partner Eisai Co released a final analysis of 856 patients in a Phase 2 clinical study in...

Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...

Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New Management As A Catalyst For Growth Leerink analyst Joseph Schwartz noted several opportunities could create a significant amount of shareholder value, including the...

U.S. stocks were little changed on Wednesday as investors found no new catalysts to maintain a bull rally, especially ahead of Friday's employment report and no new major developments arising from the Ukraine/Russia stand-off. The Beige Book, released at 2:00 pm, confirmed what most already...

Weight Watchers International (NYSE: WTW) shares are in a freefall Friday after missing Q4 EPS by $0.07 and slashing FY2014 guidance from $2.73 to $1.30-$1.60. In Friday’s trading, Weight Watchers is off by 26 percent at $22.65. This is the lowest level for the issue since April 23, 2009, when...